{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Nashville&page=28&state=Tennessee",
    "query": {
      "state": "Tennessee",
      "city": "Nashville",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 10867,
    "total_pages": 1087,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Nashville&page=29&state=Tennessee&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Nashville&page=27&state=Tennessee&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T23:54:34.481Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01313299",
      "title": "Dysport® Adult Upper Limb Spasticity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nervous System Disorders"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 243,
      "start_date": "2011-08",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-11-04T23:54:34.481Z",
      "location_count": 15,
      "location_summary": "Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 10 more",
      "locations": [
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01313299"
    },
    {
      "nct_id": "NCT07214532",
      "title": "Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Carcinoma, Ductal, Breast",
        "Receptors, Estrogen (for ER-positive Requirement)"
      ],
      "interventions": [
        {
          "name": "ctDNA-Guided Treatment Strategy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Natera, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 725,
      "start_date": "2026-05-08",
      "completion_date": "2037-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-11-04T23:54:34.481Z",
      "location_count": 49,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07214532"
    },
    {
      "nct_id": "NCT06611163",
      "title": "A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Genital Psoriasis"
      ],
      "interventions": [
        {
          "name": "Tildrakizumab 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2025-03-21",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-11-04T23:54:34.481Z",
      "location_count": 36,
      "location_summary": "Anaheim, California • Encinitas, California • Encino, California + 30 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06611163"
    },
    {
      "nct_id": "NCT00076063",
      "title": "A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ALVAC-HIV (vCP1452)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LIPO-5",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 174,
      "start_date": "2004-03",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-11-04T23:54:34.481Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076063"
    },
    {
      "nct_id": "NCT07288398",
      "title": "LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Hypertension Associated With HFpEF"
      ],
      "interventions": [
        {
          "name": "TNX-103",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tenax Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 540,
      "start_date": "2026-03-03",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-04T23:54:34.481Z",
      "location_count": 45,
      "location_summary": "Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07288398"
    },
    {
      "nct_id": "NCT06533098",
      "title": "A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thrombocytopenia, Neonatal Alloimmune"
      ],
      "interventions": [
        {
          "name": "Nipocalimab",
          "type": "DRUG"
        },
        {
          "name": "Intravenous immunoglobulins (IVIG)",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2025-02-10",
      "completion_date": "2029-12-11",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-04T23:54:34.481Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06533098"
    },
    {
      "nct_id": "NCT04905693",
      "title": "Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis",
        "Interstitial Lung Disease",
        "Progressive Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Inhaled Treprostinil",
          "type": "DRUG"
        },
        {
          "name": "Treprostinil Ultrasonic Nebulizer",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1850,
      "start_date": "2022-09-06",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-04T23:54:34.481Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 66 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Franklin",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04905693"
    },
    {
      "nct_id": "NCT02297321",
      "title": "Evaluation of the Safety and Efficacy of the DeScribe™ Patch",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tattoos"
      ],
      "interventions": [
        {
          "name": "Describe patch",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "ON Light Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-11",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2016-09-20",
      "last_synced_at": "2026-11-04T23:54:34.481Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02297321"
    },
    {
      "nct_id": "NCT02582684",
      "title": "Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2015-12-08",
      "completion_date": "2017-09-26",
      "has_results": true,
      "last_update_posted_date": "2018-05-09",
      "last_synced_at": "2026-11-04T23:54:34.481Z",
      "location_count": 25,
      "location_summary": "Los Angeles, California • San Diego, California • Torrance, California + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02582684"
    },
    {
      "nct_id": "NCT02451176",
      "title": "Biologic Mesh Versus Synthetic Mesh in Repair of Ventral Hernias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ventral Hernia"
      ],
      "interventions": [
        {
          "name": "Davol Bard Soft Mesh synthetic",
          "type": "DEVICE"
        },
        {
          "name": "LifeCell Strattice Reconstructive Tissue Biologic",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Michael Rosen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 253,
      "start_date": "2015-04",
      "completion_date": "2021-04-01",
      "has_results": true,
      "last_update_posted_date": "2022-09-07",
      "last_synced_at": "2026-11-04T23:54:34.481Z",
      "location_count": 4,
      "location_summary": "St Louis, Missouri • Cleveland, Ohio • Greenville, South Carolina + 1 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02451176"
    }
  ]
}